GZGudrun Zulehner

Gudrun Zulehner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gudrun Zulehner has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Altered EEG in Creutzfeldt-Jakob Disease

    by Evelyn Berger-Sieczkowski, Gudrun Zulehner, Sigrid Klotz, Guenther Regelsberger, Lukas Haider, Silvia Bonelli-Nauer, Karin Trimmel, Ellen Gelpi

    Background and ObjectivesCreutzfeldt-Jakob disease (CJD) is a rapidly progressive neurodegenerative disease characterized by significant changes in EEG and structural alterations on MRI. Both are i...

  • Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing

    by Martin Krenn, Matias Wagner, Helena Schuller, Isabel Pugna, Jakob Rath, Gudrun Zulehner, Omar Keritam, Rosa Weng, Inga Koneczny, Ebe Schiavo, et al.

    Myasthenia gravis (MG) is a disorder of the neuromuscular junction, typically associated with autoantibodies (Abs) that impair neuromuscular transmission. However, approximately 10% of cases are seronegative. Emerging evidence suggests that seronegative MG (SNMG) may be mimicked by hereditary conditions, particularly congenital myasthenic syndromes (CMSs), which require different treatments. In this study, we aimed to determine the proportion of CMS among patients diagnosed with SNMG. We used whole-exome sequencing (WES) in adult patients (aged ≥18 years) diagnosed with SNMG who were enrolled at 3 Austrian tertiary neuromuscular centers between August 2022 and January 2024. Genetic testing was conducted in individuals who remained seronegative after comprehensive serologic testing to exclude Abs against (clustered) acetylcholine receptors, muscle-specific kinase, lipoprotein receptor-related protein 4, and voltage-gated calcium channels. Moreover, we aimed to analyze clinical and demographic factors associated with the likelihood of receiving a molecular diagnosis. A total of 50 patients with SNMG (35 [70%] female) were referred for exome-based genetic screening. The median age at disease onset was 35 years (interquartile range 24.0-46.0 years). Seven patients (14%) were genetically diagnosed with CMS through WES (4 with CHRNE and 3 with RAPSN variants). In addition, findings of uncertain clinical significance were reported in 4 cases, implicating CACNA1S, DOK7, DPAGT1, and RAPSN. Although patients with CMS tended to have a younger age at disease onset in univariate analysis (p = 0.04, r = 0.29), no clinical or demographic factors remained significantly associated with a molecular diagnosis after correction for multiple testing. Only 1 patient with a confirmed CMS diagnosis reported a positive family history. Six individuals with CMS (86%) had either received immunomodulatory treatments (n = 4) or undergone thymectomy (n = 4). Of the 4 patients with CMS receiving immunotherapies, 3 were reported to have experienced at least a partial response. Our findings provide evidence that a considerable proportion of patients diagnosed with SNMG have an underlying hereditary etiology. Notably, a (subjective) response to immunotherapies does not exclude a molecular CMS diagnosis. In conclusion, offering genetic testing to seronegative patients with myasthenic syndromes may have profound therapeutic implications.


  • Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple Sclerosis

    by Gabriel Bsteh, Harald Hegen, Nik Krajnc, Fabian Föttinger, Lukas Haider, Barbara Kornek, Fritz Leutmezer, Stefan Macher, Tobias Monschein, Markus Ponleitner, et al.

    Progression independent of relapse activity (PIRA) is the main driver of disability accumulation in relapsing multiple sclerosis (RMS). Retinal layer atrophy measured by optical coherence tomography (OCT) reflects neuroaxonal damage and is associated with PIRA. However, it remains unclear whether this association is driven by subclinical inflammatory activity or reflects true progression independent of acute inflammation. Here, we aimed to investigate the relationship between retinal layer atrophy and progression independent of relapse and MRI activity (PIRMA) to clarify the impact of subclinical inflammatory activity. From an ongoing prospective observational study, patients with RMS meeting the following criteria were included: an OCT scan conducted 3-6 months after disease-modifying treatment (DMT) initiation (rebaseline) and at least one follow-up OCT after ≥12 months. Disability accrual was defined as a composite measure comprising worsening in either Expanded Disability Status, Timed 25-Foot Walk Test, 9-Hole Peg Test, or Symbol Digit Modalities Test using a roving baseline with a 6-month confirmation interval. PIRA was defined as disability accrual without relapse between roving baseline and confirmation. PIRMA was defined as PIRA that remained radiologically silent. We evaluated associations between PIRMA and thinning of the peripapillary retinal nerve fiber layer (pRNFL) and the macular ganglion cell plus inner plexiform layer (GCIPL) using multivariable mixed-effects linear regression models adjusted for relevant covariables (age, sex, disease duration, GCIPL/pRNFL at rebaseline, and moderate vs high-efficacy DMT). A total of 210 patients with RMS (mean age 30.5 years, SD 7.9; 74.1% female) were analyzed over a median observation period of 2.3 years (range 1-5.9 years). PIRMA was observed in 28 (13.3% overall, 41.8% of all disability accruals, 54.1% of PIRA) patients, while PIRA was encountered in 50 (23.8% overall, 77.2% of all disability accruals). Multivariable models revealed that PIRMA (vs no PIRMA) was associated with significantly more pronounced thinning of both GCIPL (0.72% per year, 95% CI 0.50-0.82, p < 0.001) and pRNFL (1.05% per year, 95% CI 0.89-1.18, p < 0.001). Our findings indicate that retinal atrophy is significantly linked with PIRMA, reinforcing its potential as a biomarker of MS-related neuroaxonal degeneration that occurs independently of acute focal inflammation.


  • Open Access

    AlphaMissense prediction for the evaluation of missense variants in the diagnostic setting of neuromuscular disorders

    by Martin Krenn, Axel Schmidt, Matias Wagner, Margot Ernst, Elisabeth Graf, Gudrun Zulehner, Hakan Cetin, Fritz Zimprich, Jakob Rath

    Next-generation sequencing has improved diagnostic outcomes for neuromuscular disorders, but interpreting rare missense variants remains challenging. We evaluated AlphaMissense, a recently developed machine learning tool, for predicting missense variant pathogenicity, using 45 (likely) pathogenic variants and 21 variants of uncertain significance from 58 deeply phenotyped patients. AlphaMissense predicted 69% of pathogenic variants correctly, but also classified 62% of variants of uncertain significance as pathogenic. Median AlphaMissense scores were not significantly different between pathogenic and uncertain variants. Overall, AlphaMissense accurately predicted the pathogenicity of most missense variants, but may be limited in certain functional contexts, highlighting the need for disease-specific interpretation approaches.


  • Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity

    by Gabriel Bsteh, Marie L. Aicher, Janette F. Walde, Nik Krajnc, Lukas Haider, Gerhard Traxler, Christiane Gradl, Anke Salmen, Katharina Riedl, Paulina Poskaite, et al.

    Isolated value of MRI metrics in relapsing multiple sclerosis (RMS) as a surrogate marker of response to disease-modifying treatment (DMT) and, thus, as decision criteria for DMT escalation in the absence of clinical signs of disease activity is still a matter of debate. The aim of this study was to investigate whether DMT escalation based on isolated MRI activity affects clinical outcome. Combining data from 5 MS centers in Austria and Switzerland, we included patients with RMS aged at least 18 years who (1) had initiated first-line, low-to-moderate-efficacy DMT (interferon β, glatiramer acetate, teriflunomide, or dimethyl fumarate) continued for ≥12 months, (2) were clinically stable (no relapses or disability progression) on DMT for 12 months, (3) had MRI at baseline and after 12 months on DMT, and (4) had available clinical follow-up for ≥2 years after the second MRI. The primary endpoint was occurrence of relapse during follow-up. The number of new T2 lesions (T2L) and DMT strategy (continuing low-/moderate-efficacy DMT vs escalating DMT) were used as covariates in regression analyses. A total of 131 patients with RMS, median age of 36 (25th-75th percentiles: 29-43) years, 73% women, were included and observed over a median period of 6 (5-9) years after second MRI. Sixty-two (47%) patients had relapse. Patients who continued first-line DMT had a 3-fold increased risk of relapse given 2 new T2L (hazard ratio [HR] 3.2, lower limit [LL] of 95% CI: 1.5) and a 4-fold increased risk given ≥3 new T2L (HR 4.0, LL-CI: 2.1). Escalation of DMT lowered the risk of relapse in patients with 2 new T2L by approximately 80% (HR 0.2, upper limit [UL] of 95% CI: 1.3) and with ≥3 new T2L by 70% (HR 0.3, UL-CI: 0.8). In case of only 1 new T2L, the increased risk of relapse and the treatment effect did not reach statistical significance of 5%. In our real-world cohort of patients clinically stable under low-to-moderate-efficacy DMT, escalation of DMT based on isolated MRI activity decreased risk of further relapse when at least 2 new T2L had occurred. This study provides Class III evidence that clinically stable patients with MS on low-/moderate-efficacy DMT with ≥3 new T2L on MRI who escalate DMT have a reduced risk of relapse and Expanded Disability Status Scale progression.


  • Open Access

    Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis

    by Gabriel Bsteh, Harald Hegen, Patrick Altmann, Michael Auer, Klaus Berek, Franziska Di Pauli, Barbara Kornek, Nik Krajnc, Fritz Leutmezer, Stefan Macher, et al.

    Background: The optic nerve has been recommended as an additional region for demonstrating dissemination in space (DIS) in diagnostic criteria for multiple sclerosis (MS). Objective: To investigate whether adding the optic nerve region as determined by optical coherence tomography (OCT) as part of the DIS criteria improves the 2017 diagnostic criteria. Methods: From a prospective observational study, we included patients with a first demyelinating event who had complete information to assess DIS and a spectral-domain OCT scan obtained within 180 days. Modified DIS criteria (DIS+OCT) were constructed by adding the optic nerve to the current DIS regions based on validated thresholds for OCT inter-eye differences. Time to second clinical attack was the primary endpoint. Results: We analyzed 267 MS patients (mean age 31.3 years [SD 8.1], 69% female) during a median observation period of 59 months (range: 13 - 98). Adding the optic nerve as a fifth region improved the diagnostic performance by increasing accuracy (DIS+OCT 81.2% vs. DIS 65.6%,) and sensitivity (DIS+OCT 84.2% vs. DIS 77.9%) without lowering specificity (DIS+OCT 52.2% vs. DIS 52.2%). Fulfilling DIS+OCT criteria (≥2 of 5 DIS+OCT regions involved) indicated a similar risk of a second clinical attack (HR 3.6, CI 1.4 – 14.5) compared to a 2.5-fold increased risk when fulfilling DIS criteria (HR 2.5, CI 1.2 – 11.8). When the analysis was conducted according to topography of the first demyelinating event, DIS+OCT criteria performed similarly in both optic neuritis and non–optic neuritis. Conclusions: Addition of the optic nerve, assessed by OCT, as a fifth region in the current DIS criteria improves diagnostic performance by increasing sensitivity without lowering specificity. Classification of Evidence: This study provides Class II evidence that adding the optic nerve as determined by optical coherence tomography (OCT) as a fifth dissemination in space (DIS) criterion to the 2017 McDonald criteria improves diagnostic accuracy.


  • Open Access

    Lower Serum Cholesterol Levels as a Risk Factor for Critical Illness Polyneuropathy: A matched Case-Control Study

    by Gudrun Zulehner, Stefan Seidel, Alexander Polanz, Christian Schörgenhofer, Paulus Rommer, Marieke Merrelaar, Dominik Roth, Harald Herkner, Sybille Behrens, Calvin Lukas Kienbacher

    Background: Critical illness polyneuropathy (CIP) is a frequent and underdiagnosed phenomenon among intensive care unit patients. The lipophilic nature of neuronal synapses may result in the association of low serum cholesterol levels with a higher rate of CIP development. We aimed to investigate this issue in critically ill patients. Methods: All cases diagnosed with CIP in our tertiary care hospital between 2013 and 2017 were 1:1 matched with controls without the condition by age, sex, and ICD diagnoses. The main risk factor examined was the difference between initial and minimum serum cholesterol levels. Other predictors were serum markers of acute inflammation. Results: We included 67 cases and 67 controls (134 critically ill patients, 49% female, 46% medical). Minimum serum cholesterol levels were lower in the cases (median difference: -24, 95% CI [-39, -9], mg/dl). A conditional logistic regression model controlling for the patients’ length of CCU stay showed a 2.2% increase in odds (odds ratio 1.022, 95% CI [1.006, 1.037], p=0.007) for the development of CIP for every 1 mg/dl decrease in serum cholesterol levels between the initial and lowest serum concentrations. Cholesterol levels decreased more profoundly in cases than controls (median: -74 (IQR -115 to -24) vs. ‑22 (IQR -53 to 0), median difference: -36, 95% CI [-59, -13]), mg/dl). We found significant median differences across matched pairs in maximum serum C-reactive protein (8.9, 95% CI [4.56, 13.24], mg/dl), minimum albumin (-4.2, 95% CI [-6.7, -1.7], g/l) and lowest cholinesterase levels (-0.72, 95% CI [-1.05, -0.39], U/l). Conclusion: Lower minimum cholesterol levels and more pronounced decreases in cholesterol levels during critical care unit hospitalizations may be a risk factor for CIP.

  • Open Access

    The diagnostic and prognostic utility of repetitive nerve stimulation in patients with myasthenia gravis

    by Matthias Tomschik, Eva Renaud, Fiona Jäger, Chiara Paternostro, Jakob Rath, Walter Rinner, Gudrun Zulehner, Fritz Zimprich, Hakan Cetin

    Repetitive nerve stimulation (RNS) is a standard test for the diagnosis of myasthenia gravis (MG), where decrement of compound muscle action potentials (CMAP) corresponds to clinical muscle fatigability. Our aim was to ascertain the diagnostic and prognostic utility of RNS in MG patients. This study included MG patients treated between 01/2000 and 12/2016, with an observational period of at least one year and a minimum of two neurological examinations. Clinical and electrophysiological data were retrospectively gathered from patient records, and CMAP decrement was correlated with autoantibody titers and clinical disease severity at different time points. Ninety-four patients were included, with 88.3% of the cohort testing positive for acetylcholine receptor autoantibodies (AChR-Abs). RNS sensitivity was higher in patients with generalized disease (71.6%) than in purely ocular MG (38.5%). CMAP decrement did not significantly correlate with AChR-Ab titers, nor with clinical symptom severity at the time of testing or last follow up. However, there was a significant correlation between CMAP decrement and the worst recorded clinical status on a group level. RNS testing is more sensitive in generalized disease and AChR-Ab positive patients, but our data do not support RNS as a tool for long-term outcome prediction. Future studies with a prospective study design could help to overcome a number of limiting factors discussed in our study.


  • Open Access

    Retinal Layer Thinning After Optic Neuritis Is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis

    by Gabriel Bsteh, Nik Krajnc, Katharina Riedl, Patrick Altmann, Barbara Kornek, Fritz Leutmezer, Stefan Macher, Christoph Mitsch, Philip Pruckner, Paulus Stefan Rommer, et al.

    Background and Objectives Remission of relapses is an important contributor to both short- and long-term prognosis in relapsing multiple sclerosis (RMS). In MS-associated acute optic neuritis (MS-ON), retinal layer thinning measured by optical coherence tomography (OCT) is a reliable biomarker of both functional recovery and the degree of neuroaxonal damage. However, prediction of non-ON relapse remission is challenging. We aimed to investigate whether retinal thinning after ON is associated with relapse remission after subsequent non-ON relapses. Methods For this longitudinal observational study from the Vienna MS database, we included patients with MS with (1) an episode of acute ON, (2) available spectral domain OCT scans within 12 months before ON onset (OCTbaseline), within 1 week after ON onset (OCTacute), and 3–6 months after ON (OCTfollow-up), and (3) at least 1 non-ON relapse after the ON episode. Subsequent non-ON relapses were classified as displaying either complete or incomplete remission based on change in the Expanded Disability Status Scale score assessed 6 months after relapse. Association of retinal thinning in the peripapillary retinal nerve fiber layer (ΔpRNFL) and macular ganglion cell and inner plexiform layer (ΔGCIPL) with incomplete remission was tested by multivariate logistic regression models adjusting for age, sex, disease duration, relapse severity, time to steroid treatment, and disease-modifying treatment status. Results We analyzed 167 patients with MS (mean age 36.5 years [SD 12.3], 71.3% women, mean disease duration 3.1 years [SD 4.5]) during a mean observation period of 3.4 years (SD 2.8) after the ON episode. In 61 patients (36.5%), at least 1 relapse showed incomplete remission. In the multivariable analyses, incomplete remission of non-ON relapse was associated with ΔGCIPL thinning both from OCTbaseline to OCTfollow-up and from OCTacute to OCTfollow-up (OR 2.4 per 5 μm, p < 0.001, respectively), independently explaining 29% and 27% of variance, respectively. ΔpRNFL was also associated with incomplete relapse remission when measured from OCTbaseline to OCTfollow-up (OR 1.9 per 10 μm, p < 0.001), independently accounting for 22% of variance, but not when measured from OCTacute to OCTfollow-up. Discussion Retinal layer thinning after optic neuritis may be useful as a marker of future relapse remission in RMS.


  • Open Access

    Long‐term outcome after COVID‐19 infection in multiple sclerosis: A nation‐wide multicenter matched‐control study

    by Gabriel Bsteh, Hamid Assar, Christiane Gradl, Bettina Heschl, Maria‐Sophie Hiller, Nik Krajnc, Franziska Di Pauli, Harald Hegen, Gerhard Traxler, Fritz Leutmezer, et al.

    Background and purpose: Long‐term outcome after COVID‐19 in patients with multiple sclerosis (pwMS) has scarcely been studied, and controlled data are lacking. The objective of this study was to compare long‐term outcome after COVID‐19 in pwMS to a matched control group of pwMS without COVID‐19.Methods: We included pwMS with polymerase chain reaction‐confirmed diagnosis of COVID‐19 and ≥6 months of follow‐up and, as a control group, pwMS matched 1:1 for age, sex, disability level, and disease‐modifying treatment type.Results: Of 211 pwMS with COVID‐19 (mean age = 42.6 years [SD = 12.2], 69% female, median Expanded Disability Status Scale = 1.5 [range = 0–7.5], 16% anti‐CD20), 90.5% initially had a mild COVID‐19 course. At follow‐up, 70% had recovered completely 3 months (M3) after COVID‐19, 83% after 6 months (M6), and 94% after 12 months (M12). Mild initial COVID‐19 course was the only significant predictor of complete recovery (odds ratio [OR] = 10.5, p < 0.001). The most frequent residual symptoms were fatigue (M3: 18.5%, M6: 13.7%, M12: 7.3%), hyposmia (M3: 13.7%, M6: 5.2%, M12: 1.7%), and dyspnea (M3: 7.1%, M6: 6.6%, M12: 2.8%). Compared to matched controls, fatigue, hyposmia, and dyspnea were significantly more frequent at M3 and still slightly more frequent at M6, whereas there was no difference at M12. pwMS with COVID‐19 had neither a significantly increased risk for relapses (OR = 1.1, p = 0.70) nor disability worsening (OR = 0.96, p = 0.60).Conclusions: Long‐term outcome of COVID‐19 is favorable in a large majority of pwMS, with only a small proportion of patients suffering from persistent symptoms usually resolving after 3–6 months. COVID‐19 is not associated with increased risk of relapse or disability.